EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswireDec 16 20:00

H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22

Futu NewsDec 6 01:31 · Ratings

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow JonesDec 5 19:30 · Ratings

EyePoint Pharmaceuticals Analyst Ratings

BenzingaDec 5 19:18 · Ratings

Express News | EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026

BreakingsDec 4 20:00

Express News | EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration

BreakingsDec 4 20:00